Immune Design (NASDAQ: IMDZ) announced that analyses of data from three ongoing Phase 1 studies support continued development of its ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE